The KDM2B-let-7b-EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Karoopongse, Ekapun ^a   Yeung, Cecilia ^a,b   Byon, John ^b   Ramakrishnan, Aravind ^a,b   Holman, Zaneta J ^a   Jiang, Peter Y Z ^c   Yu, Qiang ^d   Deeg, H Joachim ^a,b   Marcondes, A Mario ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c The Everett Clinic   (United States)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

3 DEAZANEPLANOCIN A; AZACITIDINE; CYCLIN D1; HISTONE DEMETHYLASE; MICRORNA; MICRORNA LET 7B; PROTEIN KDM2B; PROTEIN P16; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; EZH2 PROTEIN, HUMAN; F BOX PROTEIN; HISTONE; KDM2A PROTEIN, HUMAN; MIRNLET7 MICRORNA, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

ARTICLE; BONE MARROW CULTURE; CD34 SELECTION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MYELODYSPLASTIC SYNDROME; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; BONE MARROW CELL; CLUSTER ANALYSIS; DRUG EFFECTS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; METABOLISM; METHYLATION; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; TUMOR CELL LINE;

AZACITIDINE; BONE MARROW CELLS; CELL LINE, TUMOR; CLUSTER ANALYSIS; EPIGENESIS, GENETIC; F-BOX PROTEINS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; HISTONES; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; METHYLATION; MICRORNAS; MOLECULAR TARGETED THERAPY; MYELODYSPLASTIC SYNDROMES; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84907168701     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107817     Document Type: Article

References (36)

1. Elias HK, Schinke C, Bhattacharyya S, Will B, Verma A, et al. (2013) Stem cell origin of myelodysplastic syndromes. Oncogene [Epub ahead of print 2013 Dec 16]-doi: 10.1038/onc.2013.520.
2. Larsson CA, Cote G, Quintas-Cardama A (2013) The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Molecular Cancer Research: MCR 11: 815-827.
3. Yamazaki J, Issa JP (2013) Epigenetic aspects of MDS and its molecular targeted therapy (Review). Int J Hematol 97: 175-182.
4. He J, Kallin EM, Tsukada Y, Zhang Y (2008) The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b). Nature Structural & Molecular Biology 15: 1169-1175.
5. Pfau R, Tzatsos A, Kampranis SC, Serebrennikova OB, Bear SE, et al. (2008) Members of a family of JmjC domain-containing oncoproteins immortalize embryonic fibroblasts via a JmjC domain-dependent process. Proc Natl Acad Sci USA 105: 1907-1912.
6. He J, Nguyen AT, Zhang Y (2011) KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 117: 3869-3880.
7. Tzatsos A, Paskaleva P, Lymperi S, Contino G, Stoykova S, et al. (2011) Lysinespecific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. J Biol Chem 286: 33061-33069.
8. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, et al. (2006) The Polycomb group protein EZH2 directly controls DNA methylation.[Erratum appears in Nature. 2007 Apr 12;446(7137): 824]. Nature 439: 871-874.
9. Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su IH, et al. (2009) Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 136: 1122-1135.
10. Li X, Xu F, Chang C, Byon J, Papayannopoulou T, et al. (2012) Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes. Haematologica 98: 414-419.
11. Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, et al. (2014) Self-renewal as a therapeutic target in human colorectal cancer. Nat Med 20: 29-36.
12. Tohyama K, Tsutani H, Ueda T, Nakamura T, Yoshida Y (1994) Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome. Br J Haematol 87: 235-242.
13. Richter T, Nahrig J, Komminoth P, Kowolik J, Werner M (1999) Protocol for ultrarapid immunostaining of frozen sections. J Clin Pathol 52: 461-463.
14. Kottakis F, Polytarchou C, Foltopoulou P, Sanidas I, Kampranis SC, et al. (2011) FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Molecular Cell 43: 285-298.
15. Skriner K, Sommergruber WH, Tremmel V, Fischer I, Barta A, et al. (1997) Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease. J Clin Invest 100: 127-135.
16. Fiskus W, Rao R, Balusu R, Ganguly S, Tao J, et al. (2012) Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clin Cancer Res 18: 6227-6238.
17. Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, et al. (2012) Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 78: 138-143.
18. Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, et al. (2011) Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Molecular Cancer 10: 40.
19. Garcia-Manero G, Fenaux P (2011) Hypomethylating agents and other novel strategies in myelodysplastic syndromes (Review). J Clin Oncol 29: 516-523.
20. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, et al. (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364: 2496-2506.
21. Makishima H, Visconte V, Sakaguchi H, Jankowska AM, Abu KS, et al. (2012) Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 119: 3203-3210.
22. Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, et al. (2010) Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 24: 756-764.
23. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, et al. (2011) Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 365: 1384-1395.
24. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, et al. (2012) Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 366: 1090-1098.
25. Hussein K, Theophile K, Busche G, Schlegelberger B, Gohring G, et al. (2010) Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res 34: 1169-1174.
26. Li J, Zhou BP (2011) Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer 11: 49.
27. Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, et al. (2011) Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol 153: 24-32.
28. Li X, Marcondes AM, Gooley TA, Deeg HJ (2010) The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. Blood 116: 2304-2314.
29. Marcondes AM, Li X, Gooley TA, Milless B, Deeg HJ (2010) Identification of DJ-1/Park-7 as a determinant of stroma-dependent and TNFα-induced apoptosis in MDS by using mass spectrometry and phosphopeptide analysis. Blood 115: 1993-2002.
30. Garcia-Manero G (2007) Modifying the epigenome as a therapeutic strategy in myelodysplasia (Review). Hematology 405-411.
31. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, et al. (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113: 1315-1325.
32. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, et al. (2012) Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 120: 2076-2086.
33. Nakagawa S, Sakamoto Y, Okabe H, Hayashi H, Hashimoto D, et al. (2014) Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells. Oncology Reports 31: 983-988.
34. Lee JK, Kim KC (2013) DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells. Biochem Biophys Res Commun 438: 647-652.
35. Puppe J, Drost R, Liu X, Joosse SA, Evers B, et al. (2009) BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Research 11: R63.
36. Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, et al. (2012) TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Clin Cancer Res 18: 4201-4212.